EGFRExon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed byT790M-Mediated Resistance

Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2017.0151
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Harborside Press, LLC


Related search